Crossbow Therapeutics
Cambridge, US · Founded 2021 · Delaware corporation · 41 employees on LinkedIn · 7 known investors
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies. The company creates next-generation T-cell engagers incorporating its proprietary T-Bolt™ molecules to enhance therapeutic potency and manufacturability.
Founders & leadership
Board
Investors · 7
MPM BioImpactBoston · $1M – $15Mvia Todd Foley · board
Pfizer Venture Investments$5M – $20M
Biotechnology Value FundreportedSan Francisco
Mirae Asset Venture Investmentreported$594K – $54M
Pfizer Venturesreported
Polaris PartnersreportedBoston · $500K – $5Mvia Alexandra Cantley · board
Taiho Ventures, LLCreportedMenlo Park
Reported raises · per SEC filings
Form D private placements$67.8M disclosed across 2 rounds · 2023–2025
▶$30.3MraisedSep 2025 · 17 investors · BiotechnologyRule 506(b)
▶$30.3MraisedSep 2025 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alexander NolteExecutive Officer
- Alexandra CantleyDirector
- Dmitri WiederschainExecutive Officer
- Sakae AsanumaDirector
- Charles BaumDirector
- Briggs MorrisonExecutive Officer, Director, Promoter
- Irena MelnikovaDirector
- Alon LazarusDirector
- Todd FoleyDirector
- Offering amount
- $80M
- Amount sold
- $30.3M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$37.6MraisedApr 2023 · 15 investors · BiotechnologyRule 506(b)
▶$37.6MraisedApr 2023 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Irena MelnikovaDirector
- Todd FoleyDirector
- Briggs MorrisonExecutive Officer, Director
- Alexandra CantleyDirector
- Geraldine PaulusExecutive Officer
- Offering amount
- $80M
- Amount sold
- $37.6M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Crossbow Therapeutics went on to found or lead other companies.
Competitors · 3
by search overlapBioworld29 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Solu26 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Relay23 shared keywordsRelay Therapeutics develops small-molecule therapeutics using its Dynamo platform, which combines experimental and computational methods to model protein motion and target proteins considered difficult to drug. Its pipeline focuses on precision oncology and genetic disease.
Companies competing with Crossbow Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Crossbow Therapeutics do?
- Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies. The company creates next-generation T-cell engagers incorporating its proprietary T-Bolt™ molecules to enhance therapeutic potency and manufacturability.
- Who are Crossbow Therapeutics's investors?
- Crossbow Therapeutics's investors include MPM BioImpact, Pfizer Venture Investments, Biotechnology Value Fund, Mirae Asset Venture Investment, Pfizer Ventures, Polaris Partners, Taiho Ventures, LLC.
- How much funding has Crossbow Therapeutics raised?
- Crossbow Therapeutics has disclosed $67.8M raised across 2 rounds.
- Where is Crossbow Therapeutics headquartered?
- Crossbow Therapeutics is headquartered in Cambridge, US.